Moore Kuehn Encourages CWBR, RXDX, RUTH, and APGN Investors to Contact Law Firm
25 mai 2023 11h51 HE
|
Moore Kuehn
NEW YORK, May 25, 2023 (GLOBE NEWSWIRE) -- Moore Kuehn, PLLC, a law firm focusing in securities litigation located on Wall Street in downtown New York City, is investigating potential claims...
Moore Kuehn Encourages RXDX, STSA, CHRA, and BLU Investors to Contact Law Firm
18 avr. 2023 11h32 HE
|
Moore Kuehn
NEW YORK, April 18, 2023 (GLOBE NEWSWIRE) -- Moore Kuehn, PLLC, a law firm focusing in securities litigation located on Wall Street in downtown New York City, is investigating potential claims...
Prometheus Biosciences Reports Fourth Quarter and Full-Year 2022 Financial Results and Highlights Recent Corporate Progress
28 févr. 2023 16h00 HE
|
Prometheus Biosciences
– Reported strong efficacy and favorable safety results for PRA023 in ARTEMIS-UC and APOLLO-CD Phase 2 Studies – – Prometheus intends to advance PRA023 into Phase 3 studies for UC and CD in 2023 – ...
Prometheus Biosciences Announces Positive Results for PRA023 in Both ARTEMIS-UC Phase 2 and APOLLO-CD Phase 2a Studies Enabling Pathway to Both First-in-Class and Best-in-Class Anti-TL1A mAb
07 déc. 2022 07h00 HE
|
Prometheus Biosciences
– ARTEMIS-UC trial met primary endpoint with 26.5% of patients on PRA023 achieving clinical remission compared to 1.5% of patients on placebo at Week 12 (p<0.0001) – – ARTEMIS-UC Cohort 1 met all...
Prometheus Biosciences Provides Enrollment Update in APOLLO-CD and ARTEMIS-UC Global Phase 2 Studies
08 juin 2022 08h00 HE
|
Prometheus Biosciences
- Enrollment completed ahead of schedule for APOLLO-CD Phase 2a study of PRA023 in Crohn’s disease patients - - ARTEMIS-UC Phase 2 Cohort 1 enrollment on track with completion expected 3Q 2022 - -...
Prometheus Biosciences to Participate at the Jefferies Healthcare Conference
26 mai 2022 08h00 HE
|
Prometheus Biosciences
SAN DIEGO, May 26, 2022 (GLOBE NEWSWIRE) -- Prometheus Biosciences, Inc. (Nasdaq: RXDX), a clinical-stage biotechnology company pioneering a precision medicine approach for the discovery,...
Prometheus Biosciences Reports First Quarter 2022 Financial Results and Highlights Recent Corporate Progress
12 mai 2022 16h01 HE
|
Prometheus Biosciences
- Advanced and expanded development of PRA023 across three immune-mediated indications - - Topline results from ARTEMIS-UC and APOLLO-CD Phase 2 studies on track for fourth quarter 2022 - -...
Prometheus Biosciences Initiates Third Phase 2 Study of PRA023 for Systemic Sclerosis-Associated Interstitial Lung Disease (SSc-ILD)
30 mars 2022 08h00 HE
|
Prometheus Biosciences
- First therapeutic candidate for the treatment of SSc-ILD targeting both key fibrotic and inflammatory pathways - - ATHENA-SSc-ILD Phase 2 topline results expected first-half 2024 - - FDA has...
Prometheus Biosciences Reports Second Quarter 2021 Financial Results and Highlights Recent Corporate Progress
11 août 2021 16h01 HE
|
Prometheus Biosciences
- Initiated Phase 2 study of PRA023 and its companion diagnostic in Ulcerative Colitis (UC) and Phase 2a study of PRA023 and its companion diagnostic in Crohn’s disease (CD) - - Phase 1a trial...
Fred Hassan, Former CEO of Schering-Plough and Former Chairman of Bausch & Lomb, Joins Prometheus Biosciences Board
17 mai 2021 08h00 HE
|
Prometheus Biosciences
SAN DIEGO, May 17, 2021 (GLOBE NEWSWIRE) -- Prometheus Biosciences, Inc. (Nasdaq: RXDX), a clinical-stage biotechnology company pioneering a precision medicine approach for the discovery,...